Mental Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Eli Lilly
Double-blind, randomized trial shows duloxetine is effective option for DPNP management
December 17th, 2005
A double-blind, randomized multicenter trial shows that duloxetine given daily is an effective option for management of diabetic peripheral neuropathic pain. "Assess efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain (DPNP). This was a multicenter, parallel, double-blind, randomized, placebo-controlled trial that enrolled 348 patients with pain due to peripheral neuropathy caused by type 1 or type 2 diabetes mellitus," investigators in Canada report. J. Raskin and colleagues working with Eli Lilly conducted a study...
Source: Mental Health Law Weekly (2005-12-17)
|
